feed,title,long_url,short_url
MedRxiv,Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults,https://medrxiv.org/cgi/content/short/2022.05.30.22275753v1?rss=1,https://bit.ly/3x1Rrdr
MedRxiv,Lineage BA.2 dominated the Omicron SARS-CoV-2 epidemic wave in the Philippines,https://medrxiv.org/cgi/content/short/2022.05.30.22275783v1?rss=1,https://bit.ly/3adCAEZ
MedRxiv,Immunity response against mild-to-moderate breakthrough COVID-19,https://medrxiv.org/cgi/content/short/2022.05.30.22275050v1?rss=1,https://bit.ly/3PSZmCF
MedRxiv,The cost of the COVID-19 pandemic vs the cost-effectiveness of mitigation strategies in the EU/UK/EEA and OECD countries: a systematic review,https://medrxiv.org/cgi/content/short/2022.05.31.22275813v1?rss=1,https://bit.ly/3aayoWH
